XON - Intrexon Corporation

NYSE - NYSE Delayed Price. Currency in USD
14.20
+0.46 (+3.35%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close13.74
Open13.78
Bid0.00 x 2200
Ask0.00 x 900
Day's Range13.42 - 14.24
52 Week Range10.26 - 20.67
Volume950,597
Avg. Volume1,325,206
Market Cap1.857B
Beta1.59
PE Ratio (TTM)N/A
EPS (TTM)-1.04
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
Trade prices are not sourced from all markets
  • Cramer's lightning round: Medical device stocks tend to w...
    CNBC Videos2 months ago

    Cramer's lightning round: Medical device stocks tend to w...

    Jim Cramer rattles off his take on callers' favorite stocks, including a group of securities he tends to recommend.

  • GlobeNewswire3 days ago

    Research Report Identifies Acushnet, Capitol Federal Financial, Laredo Petroleum, Intrexon, Corning, and Idera Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acushnet ...

  • Why Intrexon Corporation Stock Is Slipping Today
    Motley Fool7 days ago

    Why Intrexon Corporation Stock Is Slipping Today

    A regulatory filing delay provides an unpleasant surprise to the biotech's shareholders.

  • Intrexon Reports Preliminary Earnings and Revenues for Q2
    Zacks7 days ago

    Intrexon Reports Preliminary Earnings and Revenues for Q2

    Intrexon (XON) reports preliminary second-quarter 2018 results and expects a loss of 17 cents for the quarter.

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: Omeros and Intrexon

    NEW YORK, NY / ACCESSWIRE / August 10, 2018 / U.S. markets finished mostly lower on Thursday, as broader market was dragged lower by weak performance from the industrial and energy sector matched with ...

  • PR Newswire7 days ago

    Intrexon Business Update and Conference Call

    The Company is not announcing final financial results for the quarter ended June 30, 2018 and is delaying the filing of its quarterly report on Form 10-Q.  The delay in filing the second quarter report is related to the Company's application of certain aspects of ASC 606 in the Company's first quarter Form 10-Q.  The Company will be filing an amended Form 10-Q for the first quarter of 2018.  The Company expects to file the second quarter report and amended first quarter report within the next few days. Intrexon and Epimeron, Inc., a world-class provider of gene discovery and biosynthetic pathway optimization, announced the isolation and recombinant expression of a novel gene from the opium poppy (Papaver somniferum) encoding the enzyme thebaine synthase.

  • ACCESSWIRE7 days ago

    Intrexon Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Intrexon Corporation (NYSE: XON ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:30 PM Eastern Time. ...

  • GlobeNewswire10 days ago

    Ziopharm Oncology Announces Changes to its Board of Directors

    Scott Tarriff, a member of the Board since 2015, has been elected to serve as Lead Director, succeeding Sir Murray Brennan, M.D. Both Sir Dr. Brennan and former U.S. Sen. William Wyche Fowler will step down when their terms expire on September 18, 2018, the date of the annual meeting of shareholders. Doug Pagán and Elan Ezickson have been nominated for election to the Board at the Company’s annual meeting of stockholders.

  • GlobeNewswire10 days ago

    AquaBounty Technologies, Inc. Results for the quarter and six months ended June 30, 2018

    MAYNARD, Mass., Aug. 07, 2018-- AquaBounty Technologies, Inc., a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation, ...

  • PR Newswire14 days ago

    Intrexon to Present at the Jefferies 2018 Global Industrials Conference

    GERMANTOWN, Md. , Aug. 3, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...

  • PR Newswire15 days ago

    Intrexon to Announce Second Quarter and First Half 2018 Financial Results on August 9th

    GERMANTOWN, Md. , Aug. 2, 2018 /PRNewswire/ --   Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...

  • What's in Store for Intrexon (XON) This Earnings Season?
    Zacks16 days ago

    What's in Store for Intrexon (XON) This Earnings Season?

    Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.

  • GlobeNewswire17 days ago

    Ziopharm Oncology to Announce Second Quarter 2018 Financial Results, Host Conference Call Aug. 8

    The webcast will be recorded and available for replay on the Company's website for two weeks. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.

  • GlobeNewswire22 days ago

    Ziopharm Oncology Board Responds to Recent Stock Price Decline

    Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today responded to the recent stock price decline and announced it expects to add new members to the Company’s Board of Directors and expand its management team. “Over the past year, our Controlled IL-12 and Sleeping Beauty cell therapy platform technologies have progressed, providing a strong scientific foundation for the Company.

  • The Global Cannabis Market Is Set To Explode
    Oilprice.com25 days ago

    The Global Cannabis Market Is Set To Explode

    2018 saw the North American cannabis market explode, peaking when Canada announced it will fully legalize recreational use, but the opportunities for this commodity are only just beginning

  • ACCESSWIRElast month

    Free Technical Research on Intrexon and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.

  • Company Lends Stock to Bank. Bank Shorts Stock to Company's CEO. Any Questions?
    Bloomberglast month

    Company Lends Stock to Bank. Bank Shorts Stock to Company's CEO. Any Questions?

    Intrexon Corp. is a $1.9 billion market-cap biotech company that issued $200 million of convertible bonds last week. The way convertible bonds work is that they are bonds that can be converted into stock: You sell them for $1,000, and at the end of (in this case) five years investors either get a fixed number of shares of stock (if the stock is up more than a certain amount over those five years) or just get their $1,000 back. If short sellers are already selling a lot of a company’s stock short, then there may not be much stock left to borrow.

  • Deutsche Bank Brought in Some Help
    Bloomberglast month

    Deutsche Bank Brought in Some Help

    Hedge fund managers will decide that they’re better at operating businesses than business operators are, and become activists, and get companies to adopt their operational suggestions. As a private-equity investor, Cerberus often provides advice for a fee to its portfolio companies.

  • PR Newswire2 months ago

    Intrexon Announces Pricing of Offerings of Convertible Senior Notes and Common Stock

    GERMANTOWN, Md., June 29, 2018 /PRNewswire/ -- Intrexon Corporation (XON) (the "Company") today announced that it has priced its offering of $200.0 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2023 (the "Notes") in an underwritten offering registered with the Securities and Exchange Commission (the "SEC"). The Notes will be senior unsecured obligations of the Company and will bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2019.  The Notes will mature on July 1, 2023, unless earlier repurchased or converted in accordance with their terms.  Prior to April 1, 2023, the Notes will be convertible at the option of the holder only upon the occurrence of certain events and during certain periods.  On or after April 1, 2023, the Notes will be convertible at the option of the holder at any time until the business day immediately preceding the maturity date.

  • GlobeNewswire2 months ago

    Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®

    Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced that it has enrolled the first patient in its Phase 1 clinical trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, in adult patients with recurrent glioblastoma (rGBM). “We are excited about the first-ever dosing of this combination and its potential to bring a potent and controlled anti-tumor immune response to glioblastoma,” said Francois Lebel, M.D., Executive Vice President, Research and Development, Chief Medical Officer at Ziopharm. “By controlling interleukin 12, Ad-RTS-hIL-12 plus veledimex already has shown it can recruit killer T cells into the tumor and increase expression of checkpoints in this microenvironment.

  • PR Newswire2 months ago

    Intrexon Announces Proposed Offerings of Convertible Senior Notes and Common Stock

    GERMANTOWN, Md., June 27, 2018 /PRNewswire/ -- Intrexon Corporation (XON) (the "Company") today announced that it intends to offer and sell, subject to market and other conditions, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in an underwritten offering registered with the Securities and Exchange Commission (the "SEC").  The Company expects to grant the underwriters of the Notes a 30-day option to purchase up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if any. The Notes will be senior unsecured obligations of the Company, and interest will be payable semi-annually in arrears.  The Notes will be convertible into cash, shares of the Company's common stock ("Common Stock") or a combination thereof, at the Company's election.  The interest rate, conversion rate and other terms of the Notes will be determined upon pricing of the offering of the Notes.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Intrexon

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / U.S. equities slumped on Tuesday as global trade concerns grew after President Trump threatened to impose an additional $400 billion in tariffs on goods from ...

  • PR Newswire2 months ago

    Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes

    Oxitec, Ltd. ("Oxitec"), a wholly owned subsidiary of Intrexon Corporation (XON), today announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere. The parties will build on Oxitec's successful deployment of Friendly™ Aedes mosquitoes to reduce the vector that spreads dengue, Zika and other diseases and apply the self-limiting and male-selecting technology to anopheline vectors that can spread malaria in endemic regions in the Americas, eastern Africa and South Asia.

  • PR Newswire2 months ago

    Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes

    Oxitec, Ltd. ("Oxitec"), a wholly owned subsidiary of Intrexon Corporation (XON) (XON), today announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere. The parties will build on Oxitec's successful deployment of Friendly™ Aedes mosquitoes to reduce the vector that spreads dengue, Zika and other diseases and apply the self-limiting and male-selecting technology to anopheline vectors that can spread malaria in endemic regions in the Americas, eastern Africa and South Asia.

  • CNBC2 months ago

    Cramer's lightning round: Medical device stocks tend to win big

    Jim Cramer rattles off his take on callers' favorite stocks, including a group of securities he tends to recommend.